Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Payables: 2021-2025

Historic Payables for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $6.2 million.

  • Kiniksa Pharmaceuticals International's Payables fell 26.15% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.1 million, marking a year-over-year decrease of 35.38%. This contributed to the annual value of $2.0 million for FY2024, which is 75.27% down from last year.
  • Kiniksa Pharmaceuticals International's Payables amounted to $6.2 million in Q3 2025, which was down 31.33% from $9.0 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Payables ranged from a high of $9.0 million in Q2 2025 and a low of $648,000 during Q2 2023.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median Payables value was $5.6 million (recorded in 2024), while the average stood at $4.7 million.
  • Within the past 5 years, the most significant YoY rise in Kiniksa Pharmaceuticals International's Payables was 1,040.90% (2024), while the steepest drop was 75.27% (2024).
  • Quarterly analysis of 5 years shows Kiniksa Pharmaceuticals International's Payables stood at $1.9 million in 2021, then soared by 322.86% to $7.9 million in 2022, then grew by 4.39% to $8.2 million in 2023, then slumped by 75.27% to $2.0 million in 2024, then decreased by 26.15% to $6.2 million in 2025.
  • Its Payables stands at $6.2 million for Q3 2025, versus $9.0 million for Q2 2025 and $2.0 million for Q1 2025.